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INTRODUCTION 
 
Obesity has reached epidemic proportions worldwide. Recent World 
Health Organization (WHO) projections estimate that globally in 2005 
approximately 1.6 billion adults older than 15 years were overweight and at 
least 400 million adults were obese2 . The WHO also underlines that this 
pandemic, once considered a problem only in high-income countries, is now 
dramatically on the rise in low- and middle-income countries (Developing 
countries), particularly in India & China. 
Obesity  is now  the  silent  epidemic  of  this  century  throughout  the  
world.  26th  November of  every year  is  celebrated  as “ ANTI  OBESITY  
DAY “ .  In  India  more  than  20  million  people  are  suffering  from  
obesity which  should  be  the  root  cause  of  most  of  the  problems   in  
the  future. 
The  studies  say  that  every  extra  10kg  of  weight  gain reduces  
life  expectancy  by  3yrs. Nowadays  the person’s  life  is  of  hectic lifestyle  
so   they  start   resort  to  crash  dieting for reducing weight.  Crash dieting 
(measures  taken  to  reduce  weight)  usually results in loss of body water 
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and mass, and not fat. There is also a rebound of weight gain, driven by the   
hormone     ghrelin,  or  the   hunger hormone. 
             Obesity is a disease of energy storage  whose etiology is 
cumulatively greater energy intake than is needed for daily activities. The 
excess energy is stored in the form of fat, carbohydrate, or protein.  
The pathology is, enlarged fat cells. The extent to which these 
enlarged cells produce detrimental health consequences depends on two 
major factors.  
The first   is  the   mass of   fat,  which    leads to  changes  in body 
configuration . The second is the location of the fat cells.  
The principal detrimental metabolic consequences occur when fat 
cells enlarge. Increased intra-abdominal or visceral fat may accentuate this 
problem. 
Production of adipocytokines, inflammatory markers, vascular factors, 
and leptin from enlarged visceral fat cells causes the primary metabolic 
derangements, such as diabetes, atherogenic dyslipidemia (decreased HDL 
cholesterol and increased triglycerides), and release of inflammatory 
markers such as interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α) or 
procoagulant factors such as plasminogen activator inhibitor 1 (PAI-1) . 
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Obesity is a disease and its pathology lies in the increased size and 
number of fat cells .In adults, the upper limits of the total no of normal fat 
cells range from 40 x 109  to 60 x 109. The number of fat cells increases most 
rapidly during late childhood and puberty. 
The number  of  fat cells can increase three- to fivefold when obesity 
occurs in childhood or adolescence. 
Hypertrophic obesity 
Enlarged fat cells is the pathologic sign of obesity2. Enlarged fat cells 
tend to correlate with an android or truncal fat distribution, and are often 
associated with metabolic disorders such as glucose intolerance, 
dyslipidemia, hypertension, and coronary artery disease.  
These derangements occur because large fat cells secrete more  
peptides and metabolites, such as IL-6, TNF-α, leptin, and PAI-1. The 
exception is adiponectin, whose secretion decreases as fat cells enlarge. 
Hypercellular obesity 
An increase in the number of fat cells usually occurs when obesity 
develops in childhood. When it begins in early or middle childhood, the type 
of obesity tends to be more severe. Increased numbers of fat cells may also 
occur in adult life, and this is to be expected when the body mass index 
(BMI) is >40 kg/m2. 
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Measuring fat distribution is important, because increased visceral fat 
predicts the development of health risks better than the total body fat. The 
concept that android or male fat distribution was associated with diabetes 
and heart disease was originally suggested by Vague in 1948  and is now 
widely accepted.  
The distribution of body fat can be estimated by a variety of 
techniques. The ratio of waist circumference to hip circumference (WHR) 
was used in the pioneering studies that brought scientific recognition in the 
1980s to the relationship of centrally located fat to the risk of developing 
heart disease, diabetes, and other chronic problems associated with obesity .  
  More precise estimates of visceral fat can be obtained by computed 
tomography (CT)  or magnetic resonance imaging.  
Overweight is now recognized as a risk factor for cardiovascular 
disease and as a contributing factor in the development of other diseases, 
most notably diabetes and gall bladder disease. In this context, it is 
important to evaluate and treat the obesity  so as to reduce the overall 
likelihood for developing disease and to reduce the social consequences of 
being obese. 
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Overweight, central or abdominal fat, weight gain after age 20 years, 
and a sedentary lifestyle all increase health risks and increase economic 
costs of obesity. Intentional weight loss by overweight individuals, on the 
other hand, reduces these risks. Although data are not yet available, 
researchers widely believe that long-term intentional weight loss lowers 
overall mortality, particularly from diabetes, gallbladder disease, 
hypertension, heart disease, and some types of cancer. 
We  know  that Visceral adiposity (VAT) is associated with many 
metabolic risk factors, metabolic syndrome, diabetes, and CVD’s. In the 
clinical setting, measurement of VAT by CT or MRI is not used outside of 
research protocols13. In clinical practice, we can use anthropometric 
measurements such as WC or WHR to estimate central adiposity. 
It  has become the sixth most important risk factor contributing to the 
overall burden of chronic disease worldwide. Obesity is increasingly 
observed in children.  Obesity is closely associated with (although not 
identical to) metabolic syndrome, which is defined as a cluster of risk factors 
that increases cardiovascular risk and often is linked to obesity. 
Recently, it has been recognized that obesity is not only a 
cardiovascular risk factor, but also a major risk factor for kidney failure. The 
final common pathway involves preglomerular vasodilatation with resultant 
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glomerular hypertrophy and hyperfiltration. This hyperfiltration ultimately 
results in glomerulosclerosis . This can be detected in the earliest  stage  
itself  by measuring  microalbuminuria in the  urine. 
 One of the common findings in patients with metabolic syndrome is 
microalbuminuria. There is ongoing discussion about whether 
microalbuminuria, in metabolic syndrome, is due to  obesity, or due to 
diabetes, or  hypertension.  
Whether microalbuminuria in visceral  obesity  reflects  specific 
glomerular damage or is the marker of generalized endothelial cell 
dysfunction is still debatable. In view of the known podocyte/endothelial cell 
interaction, presumably both explanations are  true8. 
Weisinger et al  provided the first description of focal segmental 
glomerulosclerosis as a specific renal complication of morbid obesity.This 
observation has now been confirmed in many studies.  
It  has been  shown that  after weight loss, induced by bariatric 
surgery, markers of kidney damage, including albuminuria and proteinuria, 
as well as kidney function, have improved in multiple case reports36. 
By the time clinical signs pointing to kidney involvement in  obese  
and metabolic syndrome persons  are found, specifically  like 
macroalbuminuria  and  reduced  glomerular  filtration  rate, the horse has 
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already left the barn (although there is some recent evidence of 
reversibility). 
It is  therefore  important to look at the very earliest changes, like 
measuring  microalbuminuria  in  urine to  devise targeted interventions like  
strategies  for  weight  reduction, drug  therapy  & surgical methods to 
reduce  weight.  Only then will we be able to nip obesity-related kidney 
disease in the bud. 
So  with  this background  in  mind , this  case  control  study    of  50 
selected  obese  persons  with normal  blood glucose & blood pressure, & 50 
selected  nonobese persons  with normal blood  glucose & blood pressure, 
attending  the outpatient  clinic  of  Govt  Rajaji  Hospital, Madurai  were  
compared for  the  prevalence  of microalbuminuria, as a marker of 
endothelial   dysfunction &  early  kidney  disease . 
This  study  was  undertaken  by  me in  the  department  of medicine, 
Govt  Rajaji  Hospital,  Madurai medical  college. 
It  is hoped that  this  study may  help  to prevent the  development  of  
complications in obese  persons , by  early  detection  of microalbuminuria. 
This  study  also  stresses the  importance of  weight  reduction &  life  
style  modification in  obese  persons, thereby  preventing  early  morbidity 
&  mortality. 
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REVIEW  OF  LITERATURE 
2.1.1 Microalbuminuria:  
Microalbuminuria   is   defined  as  the   excretion     of   30 to 300mg 
of albumin per day in urine1. It is not a different form or fraction of albumin 
but just a very small amount of albumin. Albumin molecule is relatively 
small and it is often the first protein to enter the urine after the kidney is 
damaged.  
 24 hr. 
Collection 
(mg / 24 hr) 
Timed 
collection  
(μg/min) 
Spot collection  
Albumin Creatinine Ratio
μg / mg  or 
mg/g 
mg/mmol 
Normal  < 30  <20  < 30  <3.4  
Microalbuminuria  30 – 300  20 – 200  30 – 300  3.4 – 33.9  
Macroalbuminuria  >300  >200  >300  >33.9  
 
Excretion of albumin in urine, in the range of 20 to 200μg/min. (30-
300mg/day) is called microalbuminuria. This range of albumin in urine 
cannot be detected by routine urine tests. The presence of increased UAE 
(Urinary albumin excretion) signals an increase in the transcapillary escape 
rate of albumin and is therefore a marker of  microvascular  disease.  
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During the last few years, a subtle increase in urinary albumin excretion 
(UAE) not detectable by routine methods, so called microalbuminuria, has 
been identified as a prognostic marker for renal and/or cardiovascular risk in 
diabetic and non-diabetic subjects [Hypertension & Obese patients]. 
Consequently, assessment of microalbuminuria is now recommended as a 
risk stratification strategy not only in diabetic subjects, but also in  
hypertensives &  obese  patients. 
Albumin is an electronegative serum protein with a molecular mass 
of 66,349 Da. After glomerular filtration, part of the albumin is reabsorbed 
by tubular epithelial cells. Proteases split the albumin molecule into 
fragments, some of which back-leak into the tubular fluid . In addition, 
albumin can reach the urine from an inflammatory lesion at any site from the 
renal pelvis to the urethra. In the absence of inflammation in the urinary 
tract, intact albumin of glomerular origin is the major source of albumin in 
the urine and only a small amount of small albumin fragments are present6. 
Albumin can be detected by several methods based on precipitation 
(boiling, sulphosalicylic acid), dye binding(biuret, tetrabromphenol, albumin 
blue 580) or immunologic detection (radioimmunoassay, nephelometry, 
immunoturibidometry). While the immune reactive methods estimate only 
complete albumin molecules recognized by antibodies, peptide fragments of 
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albumin can be assessed by dye tests and specific spectrophotometry. The 
immunologic methods are most frequently used for clinical purposes, not 
only because they are easy to use at relatively low cost, but also because 
they are able to detect small amounts of albumin in the  urine. 
2.1.2 METHODS OF MEASURING MICROALBUMINURIA 
Small concentration of albumin in the urine can be measured qualitatively by 
several methods. Radioimmunoassay was the first and most widely used 
method. Various methods to determine microalbuminuria are given in the 
table 
Method Sensitivity Time  of  assay 
Single immune  radio  diffusion 1.25mg/ml 1 day 
Electroimmunoassay 5mg/l 4 – 6 hrs 
Immunoturibidimetric   assay 5mg/l 20 – 30 min 
Radio immuno  assay 6.2mcg/l 1-2 days 
ELISA 250mcg/l 12-18 min 
Fluorescent  immuno  assay 500mcg/l 4-6 hrs 
Latex agglutinates  immune  nephelometry 750mcg/l 6 hrs 
Immune chemical semi  quantitative dipstick 20-300mg/l 5sec- 5 min 
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2.1.3 Methods to report UAE 
The concentration of urinary albumin depends on the amount of 
albumin excreted and on the urine concentration. A precise assessment is 
only possible if these two factors are considered. Methods based on timed 
urine collection or on simultaneous assessment of urine creatinine 
concentration have been used to avoid these confounders of the urinary 
albumin concentration. 
Urine  albumin  concentrations  are  standardized  for  concurrent   
creatinine  excretion thus  obtaining  UACR ( urine albumin  creatinine  
ratio). This  procedure is  based  on  the concept  that  creatinine  excretion  
is  stable &  corrects  for  unknown  urine  volumes.  
According  to  ADA the  gold  standard  for  measuring  urine  
albumin  is  a 24hr  urine  collection. Collecting and measuring albumin in 
urine samples during 24 h (mg/24 h) or timed-overnight (mg/min) is 
frequently used in specialized settings.  
In contrast, for primary care and epidemiological studies, a correction 
is performed by simultaneously assessing creatinine excretion (mg/g Cr or 
mg/mmol Cr  or µg/mg Cr ) in spot samples, collected from the first voided 
urine or at the time of the clinic visit. 
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Spot urine collection  
• Description 
Random spot measurement of the albumin-to-creatinine ratio. First 
void or other morning collections are preferred because of the diurnal 
variation in albumin excretion 
Albumin and creatinine levels are measured in a single rapid assay 
• Normal 
<30mcg of albumin/mg creatinine. 
• Abnormal 
Microalbuminuria: 30-299mcg of albumin/mg creatinine  
Clinical albuminuria: 300mcg or more of albumin/mg creatinine  
Timed urine collection  
• Description 
The amount of albumin excreted over a period of time (e.g. overnight 
or 4h collection) is measured. 
• Normal 
<20mcg of albumin/min. 
• Abnormal 
Microalbuminuria: 20-199mcg of albumin/min 
Clinical albuminuria: 200mcg or more of albumin/min 
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24-hour urine test  
• Description 
Urine is collected over a 24-hour period and albumin and creatinine 
levels measured. 
• Normal 
<30mg of albumin in 24h. 
• Abnormal 
Microalbuminuria: 30-299mg of albumin in 24h 
Clinical albuminuria: 300mg or more of albumin in 24h 
American  diabetes  association (ADA)  advises that  the  spot  urine  
collection  is  often  easy  to  carry  out  in  the O.P setting  , and  complied 
by  the  patient  easily  than  the  laborious  procedure  of  collecting  24hrs  
urine. The first void  urine  or other  morning  collections  are  best because 
of the diurnal variations in albumin  secretion. 
2.1.4 Variability of UAE 
The variability of UAE is one of the most important limitations of 
assessment for clinical purposes. It is affected by a large number of factors 
which must be kept in mind when interpreting the results.  
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Fever, vigorous exercise, heart failure, haematuria and urinary tract 
infection produce a transitory increase in UAE which is more or less 
persistent depending on the cause, the intensity and the duration of the 
respective condition. 
Urinary albumin excretion follows a circadian pattern. In normal 
volunteers, UAE decreases at nighttime in recumbent position to 
approximately 70% of the values during the period of activity. 
2.1.5 Evaluation of UAE 
Conventionally, UAE values have been categorized according to the 
presence or the absence of microalbuminuria. The presence of 
microalbuminuria points to a high cardiovascular and/or renal risk which 
requires intensification of treatment. 
Microalbuminuria (MAU)  is now considered to be an atherosclerotic 
risk factor. MAU predicts future cardiovascular disease risk in diabetic 
patients, in elderly patients, as well as in the general population. It has been 
implicated as an independent risk factor for cardiovascular disease and 
premature cardiovascular mortality.  
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Although microalbuminuria is associated with a certain degree of sub-
clinical artherosclerotic damage, it is not known how early in the 
atherosclerotic process microalbuminuria appears. 
 Epidemiological studies have shown an association between MAU 
and insulin resistance, obesity, salt sensitivity and dyslipidaemia in patients 
with essential hypertension and diabetes. The mechanisms linking 
microalbuminuria and risk for cardiovascular disease are not fully 
understood, but in subjects at risk it may be related to increased 
transvascular leakiness of albumin in systemic as well as renal vessels.  
A recent concept is that microalbuminuria is a marker of extensive 
endothelial dysfunction or generalised vasculopathy, which may lead to 
heightened atherogenic states. One possible explanation is that endothelial 
dysfunction might promote increased penetration of atherogenic lipoprotein 
particles in the arterial wall, but glycaemic status, insulin resistance, 
procoagulant state and adhesion molecules have all been implicated in the 
pathogenesis.  
Current evidence suggests  that inhibitors of the renin-angiotensin 
system (RAS) can prevent or delay the progression of microalbuminuria to 
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overt nephropathy in normotensive persons.  Whether albuminuria is a risk 
factor or just a marker for CV disease, it identifies the high-risk  patients 
who should be targeted for early, aggressive interventions against proven 
risk factors.  
If persistent microalbuminuria is confirmed, strict blood pressure 
control with added RAS inhibition should be pursued in an attempt to 
stabilise or even reduce microalbuminuria, preserve kidney function and 
possibly improve cardiovascular risk. 
The greater the reduction of UAE, the lower the cardiovascular risk. 
Monitoring UAE can therefore be clinically useful to assess the success of 
interventions. 
Risk  factors  associated  with microalbuminuria: 
 
Non modifiable 
 
Modifiable 
Well   documented  Likely 
Race/ethnicity Diabetes          Hyperlipidemia 
Male gender Hypertension          High salt  diet 
Older age Obesity       Oral contraceptives 
Low birth weight Smoking Hormone replacement therapy 
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2.1.6  PATHOPHYSIOLOGY  OF  MICROALBUMINURIA 
Glomerular  &  tubular  mechanisms 
The  intimate relationship  between low  level  albumin excretion & 
vascular permeability makes urinary  albumin excretion , highly sensitive to 
the  presence of any inflammatory process, including cardiovascular  
disease. The kidney is ideally placed to amplify any small  changes in 
systemic vascular  permeability . 
The  glomeruli  receive 25%  of  the  cardiac output.  Of the 70kg of 
albumin that pass through the  kidneys  every  24 hr, less than 0.01%  
reaches the  glomerular ultrafiltrate ( i.e, less than 7g/24 hr) and  hence  
enters the  renal  tubules. 
Almost  all filtered  albumin is reabsorbed  by  the  proximal  tubule  
via a high – affinity, low – capacity  endocytotic  mechanism, with only  10-
30mg/24hr  appearing  in  the  urine. Assuming  that , 7g of  albumin is  
filtered every  24 hr, a 1% increase  in systemic  vascular  permeability  in  
response to an  inflammatory stimulus  would  result  in an additional  70mg 
of  albumin into  the  filtrate.  Since  tubular  mechanisms for  albumin  
reabsorption  are  near  saturation, urinary  albumin excretion  would  
increase from a  maximum  of  30  to  approximately  100mg/24 hr. 
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Glomerular permeability  to  albumin  is  dependant  on  endothelial 
charge  selectivity  as  well as  size  selectivity.  The negative  charge  
conferred  on  the  glomerular  membrane by  its  constituent  glycoproteins  
plays  a  role  in  restricting  the permeability  of  glomerular  charge  
selectivity,  and  this  is  found  in  both  diabetic &  non diabetic  
populations  with  microalbuminuria.  
2.1.7  Proteins  in  normal  urine 
Charge   and  size  selectivity  normally  prevent  virtually   all  
plasma albumin, globulins  & other large molecular weight  proteins  from  
crossing the  glomerular  wall. However , if  this  barrier is  disrupted, there  
can  be leakage of  plasma proteins into  the  urine. Smaller  proteins < 
20kda  are  freely  filtered but  are  readily reabsorbed  by  the  proximal  
tubule. 
Normal  individuals  excrete < 150 mg/ day  of  total  protein  &  < 30 
mg/day of  albumin. The  remainder of  the  protein in  the  urine  is  secreted  
by  the  tubules, ( Tamm-Horsfall protein,  IgA , &  Urokinase )  and 
represents  small amounts of  filtered  β2- microglobulin,  apoproteins, 
enzymes, &  peptide hormones. 
ACE  inhibitors  & ARB’s  in  particular  are  associated  with  
renoprotection. They  can  be  given  in  this  stage  of  microalbuminuria  to 
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prevent  its  progression  to  macroalbuminuria. These  effects  are  mediated  
by reducing  intraglomerular pressure and by  inhibition  of angiotensin 
driven  sclerosing pathways, in  part  through inhibition  of  TGF-β  
mediated  pathways. 
2.1.8  Factors that  cluster with  microalbuminuria 
Microalbuminuria  may be  related to target  organ  damage  by  
several  biological  pathways: 
     1) Insulin resistance 
2) Central obesity 
3) Low  levels of  high-density  lipoprotein 
4) High  triglyceride  levels 
5) Systolic  hypertension 
6) Lack  of  nocturnal  dip in  B.P on  24 hr monitoring 
7) Salt  sensitivity 
8) Endothelial  dysfunction 
9) Hypercoagulability 
    10) Impaired  fibrinolysis 
    11) Renal   dysfunction 
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2.1.9  Interventions  to  reduce  microalbuminuria 
Endothelial  dysfunction  occurs  early in  patients  with  
microalbuminuria. Several  large  studies  have  shown  that modulating  
microalbuminuria  has  beneficial  effects. 
Non pharmacological  measures: 
These  include  weight  loss,  exercise, and  eating  a low  fat  diet, but  
most  of  the  time these  are  not  enough. 
Pharmacological agents: 
Statins,  ACE inhibitors, & ARB’s  have  been  shown  in  several  
land  mark  studies  to  decrease high  blood pressure  and  
microalbuminuria. 
Either  ACEI  or  ARB’s  should  be  used  to  reduce the  progression 
from  microalbuminuria  to  macroalbuminuria  &  the  associated  decline  
in  GFR. After  2-3 months  of  therapy , the  drug  dose is  increased until  
either  the  microalbuminuria  disappears  or  the  maximum  drug  dose  is  
reached. 
But  once  macroalbuminuria  ensues , the  likelihood  of  ESRD  is  
high. 
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2.2.1   Obesity 
Obesity results from the complex interaction of environmental factors 
that act on a genetic background that determines the susceptibility to obesity. 
Obesity results from an imbalance of energy expenditure and energy intake. 
over the last two decades, it has become clear that genetic factors play an 
important role in the determination of body weight2. 
Current definitions of obesity are based on the ratio of bodyweight (in 
kg) and height squared (in m2) and expressed as body mass index (BMI) 
with a normal BMI defined as 20–24.9, moderate overweight between 25–
29.9 and Gr I obesity as above 30 and Gr II obesity > 35 and morbid obesity 
as > 40.  In 2000, the World Health Organisation released the following 
statement: ‘Obesity is a chronic disease, prevalent in both developed and 
developing countries, and affecting children as well as adults2,5.  
Obesity  is  a leading  preventable  cause of  death worldwide, with  
increasing  prevalence in both  children  &  adults. It is defined by body 
mass index (BMI) and further evaluated in terms of fat distribution via the 
waist–hip ratio . BMI is closely related to both percentage body fat  and total  
body  fat2. 
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BMI CLASSIFICATION 
<18.5 Underweight 
18.5 – 24.9 Normal Weight 
25 – 29.9 Overweight 
30 – 34.9 Class I  Obesity 
35 – 39.9 Class  II Obesity 
>= 40 Class III Obesity 
 
2.2.2 Effects on health 
Excessive body weight is associated with various diseases, 
particularly cardiovascular diseases, diabetes mellitus type 2, obstructive 
sleep apnea, certain types of cancer, and osteoarthritis. As a result, obesity 
has been found to reduce life expectancy. 
Morbidity 
Obesity increases the risk of many physical and mental conditions. 
These comorbidities are most commonly shown in metabolic syndrome , a 
combination of medical disorders which includes: diabetes mellitus type 2,  
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high blood pressure,   high total blood cholesterol,  and  high triglyceride 
levels. 
Complications are either directly caused by obesity or indirectly 
related through mechanisms sharing a common cause such as a poor diet or a 
sedentary lifestyle.   
Health consequences fall into two broad categories: 
1) Those attributable to the effects of increased fat mass (such as 
osteoarthritis,  obstructive sleep apnea,  social stigmatization)  
2) Those due to the increased number of fat cells (diabetes, cancer, 
cardiovascular disease , non-alcoholic  fatty  liver disease)  
Increases in body fat alter the body's response to insulin, potentially 
leading to insulin resistance. Increased fat also creates a proinflammatory 
state, and a prothrombotic state. 
2.2.3 Abdominal obesity 
Visceral fat or abdominal fat , also known as organ fat or intra-
abdominal fat, is located inside the abdominal cavity, packed in between 
organs (stomach, liver, intestines, kidneys, etc.). Visceral fat is different 
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from subcutaneous fat underneath the skin, and intramuscular fat 
interspersed in skeletal muscles. 
 Fat in the lower body, as in thighs and buttocks, is subcutaneous, 
whereas fat in the abdomen is mostly visceral.  Visceral fat is composed of 
several adipose depots including mesenteric, epididymal white adipose 
tissue (EWAT)  and  perirenal depots. 
An excess of visceral fat is known as central obesity, or "belly fat", in 
which the abdomen protrudes excessively. There is a strong correlation 
between central obesity and cardiovascular disease.  Excess visceral fat is 
also linked to diabetes, insulin resistance, inflammatory diseases,  and other 
obesity-related diseases. 
Female sex hormone causes fat to be stored in the buttocks, thighs, 
and hips in women. Men are more likely to have fat stored in the belly due to 
sex hormone differences. When women reach menopause and the estrogen 
produced by ovaries declines, fat migrates from their buttocks, hips and 
thighs to their waists,  later fat is stored in the belly. 
Abdominal  fat  has a different metabolic profile—being more prone 
to induce insulin resistance. This explains to a large degree why central 
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obesity is a marker of impaired glucose tolerance and is an independent risk 
factor for cardiovascular disease (even in the absence of diabetes mellitus 
and hypertension). 
Adipose tissue  derived hormones include12: 
• Adiponectin 
• Leptin  
• Plasminogen activator inhibitor-1 (PAI-1) 
• TNFα 
• IL-6 
• Resistin  
• Estradiol (E2) 
Adipose tissue is the greatest peripheral source of aromatase in both 
males and females contributing to the production of estradiol 
Adipose tissues also secrete a type of cytokines (cell-to-cell signalling 
proteins) called adipokines (adipocytokines) which play a role in obesity-
associated complications. 
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Body fat meter 
A body fat meter is a widely available tool used to measure the 
percentage of fat in the human body. Different meters use various methods 
to determine the body fat to weight ratio. 
The  body fat meter uses the principle of bioelectrical impedance 
analysis (BIA) to determine an individual's body fat percentage. 
2.2.4  Waist-hip ratio & waist circumference13  
Waist-hip ratio or Waist-to-hip ratio (WHR) is the ratio of the 
circumference of the waist to that of the hips. It is calculated by measuring 
the smaller circumference of the natural waist (WC), usually just above the 
belly button, and dividing by the hip circumference at its widest part of the 
buttocks or hip. The ratio is applied both to women and men. Men generally 
have much less pronounced hips, relative to waist size. The acceptable waist 
circumference in men ≤ 102 cm & in women ≤ 88 cm.  
The WHR has been used as an indicator or measure of the health of a 
person, and the risk of developing serious health conditions. Research shows 
that people with "apple-shaped" bodies (with more weight around the waist) 
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face more health risks than those with "pear-shaped" bodies who carry more 
weight around the hips.  
WHR is used as a measurement of obesity, which in turn is a possible 
indicator of other more serious health conditions. 
A WHR of 0.8 for women and 0.9 for men have been shown to 
correlate strongly with general health and fertility. Women within the 0.8 
range have optimal levels of estrogen and are less susceptible to major 
diseases such as diabetes, cardiovascular disorders and ovarian cancers. Men 
with WHRs around 0.9, similarly, have been shown to be more healthy and 
fertile with less prostate cancer and testicular cancer.   
WHR has been found to be a more efficient predictor of mortality in 
older people than waist circumference or body mass index (BMI).  If obesity 
is redefined using WHR instead of BMI, the proportion of people 
categorized as at risk of heart attack worldwide increases threefold. 
  The body fat percentage is considered to be an even more accurate 
measure of relative weight. Of these three measurements, only the waist-hip 
ratio takes account of the differences in body structure. Hence, it is possible 
for two women to have vastly different body mass indices but the same 
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waist-hip ratio, or to have the same body mass index but vastly different 
waist-hip ratios. 
 
 
BMI (kg/m2)
 
Obesity 
Class 
 
Men 102 cm  
Women 88 cm 
 
Men >102 cm 
Women >88 
cm 
Waist   circumference 
Underweight 18.5    -----  -----  
Normal+ 18.5 - 24.9    -----  -----  
Overweight 25.0 - 29.9    Increased  High  
Obesity 30.0 - 34.9  I  High  Very High  
  35.0 - 39.9  II  Very High  Very High  
Extreme Obesity 40  III  Extremely High  Extremely High  
 
 
 
 
 
29 
 
Waist – Hip  Ratio: 
 
 
 
 
 
 
 
 
 Acceptable Unacceptable 
excellent good average high extreme
Male  < 0.85  0.85 - 
0.90  
0.90 - 
0.95  
0.95 - 
1.00  
> 1.00  
Female  < 0.75  0.75 - 
0.80  
0.80 - 
0.85  
0.85 - 
0.90  
> 0.90  
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2.2.5  Obesity  &  Renal  Disease 
Obesity is a recognised risk factor for the development of 
nephropathy, especially focal segmental glomerulosclerosis (FSGS).  
The structural changes occurring in human kidney as a consequence 
of obesity have been demonstrated in large retrospective studies.  
 The obesity associated FSGS differs from idiopathic FSGS in many 
ways. Distinct clinicopathological features such as glomerulomegaly, less 
severe, foot process effacement and the absence of features of the nephrotic 
syndrome despite nephrotic range proteinuria are helpful in differentiating 
this entity from the idiopathic FSGS. Obesity associated FSGS is an 
indicator of poor prognosis with nearly 50% developing advanced renal 
failure. 
Glomerular  hyperfiltration/hypertrophy  in response to the increased 
metabolic needs of obesity are postulated to lead to the development of 
glomerulosclerosis (GS) in a manner analogous to that in reduced renal mass 
states. Nevertheless, the individual risk for developing GS with obesity is 
very low.  
It is proposed that glomerular hyperfiltration/hypertrophy per se are 
not pathogenic, in the absence of an enhanced glomerular blood pressure 
(BP) transmission. The modest preglomerular vasodilation that is likely to be 
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present in the large majority of obese individuals is not sufficient to result in 
such increased BP transmission.  
However, in the small subset of obese individuals who are also born 
with a substantially reduced nephron number, there is a greater risk of 
enhanced glomerular BP transmission due to the substantially greater 
preglomerular vasodilation. Perhaps this is of greater clinical importance, 
(i.e.,) similar additive deleterious effects of obesity on glomerular BP 
transmission would be expected in individuals with reduced renal mass, 
either congenital or acquired, or with concurrent renal disease, leading to 
accelerated progression.  
Obesity is associated with the activation of RAS, increased 
sympathetic nervous system activity, and hyperinsulinaemia, all of which   
may  contribute to sodium reabsorption. A compensatory lowered renal 
vascular resistance, elevated kidney plasma flow, increased GFR, and the 
higher blood pressure associated with obesity are important in overcoming 
the increased sodium reabsorption.  
Neurohumoral factors, like angiotensin II, the sympathetic system and 
cytokines, impaired pressure natriuresis, are the adaptive changes  leading to 
increased glomerular wall stress. These adaptive changes in the presence of 
other risk factors, e.g., hyperlipidaemia and hyperglycaemia, may provoke 
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glomerulosclerosis, proteinuria, and loss of nephron function in the ‘obese 
kidney’, even before structural changes are evident. The combination of 
these potentially nephrotoxic mechanisms, including hyperfiltration and 
hypertension may initiate and perpetuate renal damage. 
Persistent obesity causes renal injury and functional nephron loss, 
contributing to elevated blood pressure, which in turn leads to further renal 
injury, thereby setting off a vicious cycle of events leading to further 
elevated blood pressure and renal injury. 
Obesity certainly is better prevented than treated. Thus, lifestyle and 
dietary modifications should be encouraged in the society to control the 
obesity pandemic and reduce the burden of obesity-related health hazards. 
Weight reduction early in the course and the use of ACE inhibitors and 
statins might improve the outcome of obesity-related renal disorders. 
2.2.6  Obesity  &  Microalbuminuria 
Obesity has been reported to be an independent risk factor for the 
development of proteinuria. In nonhypertensive subjects, the prevalence of  
microalbuminuria is positively correlated with the increase in BMI and 
increase in waist-to-hip ratios. Signs of early endothelial dysfunction 
manifested as microalbuminuria were strongly and independently associated 
with central  obesity. 
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Mechanisms of obesity inducing proteinuria and Glomerulosclerosis  
are : 
a. Glomerular hyperfiltration 
An increased renal blood flow and GFR, mediated by vasodilatation 
of afferent arterioles has been observed in obese persons31.  
The cause of these  haemodynamic changes could be related to an 
increased salt reabsorption in the loop of Henle and thus increased GFR 
through tubuloglomerular feedback. The mechanisms for increased tubular 
reabsorption are still unclear, but experimental studies have shown that 
consistently found disturbances in obesity, i.e., insulin resistance, increased 
sympathetic activity and activated reninangiotensin system (RAS), could all 
play an  important role.  
b. Hyperlipidaemia 
Obesity is commonly associated with hyperlipidemia.  Studies have 
shown hyperlipidaemia to cause mesangial proliferation and expansion due 
to LDL cholesterol and development of glomerulosclerosis   and    
progressive renal failure.   Treatment of Hyperlipidaemia  reduces  
glomerular injury in obese persons. 
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c. Role of leptin and other adipose-derived  hormones:8,11,16 
Leptin is encoded on the ‘ob’ gene and is a peptide hormone derived 
from adipose tissue and plays a critical role in the control of appetite and 
energy  expenditure. Leptin  has been shown to promote the development of 
proteinuria and FSGS. Additional direct or indirect effects of leptin on the 
kidney include natriuresis, angiotensin-2 production, increased sympathetic 
nervous activity, and stimulation of reactive oxygen species. As mainly the 
kidneys clear leptin, increased levels of leptin in chronic renal failure 
contribute to appetite  suppression. 
Adiponectin is a secretory protein expressed in adipocytes. Normal 
level  in serum  is 5 – 30 µg/ml. It  is  a potent  insulin  enhancer, it  
decreases  insulin  resistance. Adiponectin, an anti-inflammatory cytokine, is 
a product of adipose tissue and is involved in regulation of lipid and glucose 
metabolism. 
Adiponectin attenuates the endothelial inflammatory response by 
inhibiting the endothelial expression of  vascular cell and intercellular 
adhesion molecules (VCAM-1 and ICAM-1) and Eselectin which are 
triggered by inflammatory cytokines.  
Adiponectin  primarily regulates albuminuria  through its   alteration  
of  podocyte  function. It  acts  through  AMPK  pathway .Plasma 
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concentrations of adiponectin are low in visceral  obesity  & this produces  
fusion  of  podocyte foot  processes – leads to  increased  albuminuria. These  
suggest that higher adiponectin levels confer a protective effect against 
atherosclerosis. 
Manoevures  that  can  increase adiponectin  levels  are  
1) Weight  reduction 
2) RAS blockade 
3) PPAR γ agonists 
4) Metformin –increases AMPK(5’c-AMP activated protein kinase ) 
pathway – the pathway to modulate  oxidant  stress in  podocytes. 
Angiotensinogen and angiotensin II are expressed in human adipose 
tissue and these play an important role in the genesis of obesity-related 
hypertension and subsequent glomerular injury. 
Tumour necrosis factor-α  is involved in insulin resistance and 
inflammation and adipose tissue is a significant site for its synthesis. TNF-α 
is  recognised as a mediator of glomerulosclerosis and is produced by 
adipocytes5. 
Plasminogen activator inhibitor is a procoagulative agent that 
inhibits fibrinolysis and is synthesised in abundance in the adipose tissue and 
plays an important role in vascular injury and atherosclerosis. 
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2.2.7  Obesity & Structural  changes  in  the  kidney:39,40 
The changes in the  kidney  includes expansion of Bowman's capsule, 
cell proliferation in the glomeruli, thickening of glomerular and tubular 
basement membranes and increased mesangial matrix in many glomeruli, 
and increases in TGF-ß1 expression in the cortex.  
These histologic changes were associated with marked glomerular 
hyperfiltration and increased renal plasma flow, modest increases in arterial 
BP, increased plasma renin activity, and hyperinsulinemia. 
In addition to the hemodynamic alterations, there are also hormonal 
changes that could contribute to renal remodelling in obesity. Two 
possibilities include elevated plasma Ang-II levels and hyperinsulinemia, 
both of which occur in obesity.  Evidence that elevated plasma AngII and 
insulin levels may contribute to glomerular structural changes is derived 
primarily from in vitro studies of mesangial cell cultures.   
Moreover TGF-ß1 has been suggested to promote renal structural 
changes and fibrosis in several kidney disorders, including diabetic 
nephropathy and  obesity. 
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2.3   Metabolic syndrome 
Metabolic syndrome is a combination of medical disorders that 
increase the risk of developing cardiovascular disease.  Metabolic syndrome 
is also known as metabolic syndrome X, syndrome X, insulin resistance 
syndrome. 
The World Health Organization criteria  requires the presence of  
1)  Diabetes mellitus, or impaired glucose tolerance, or impaired fasting 
glucose  or  insulin resistance, AND  any  two of the following: 
    a)  Blood pressure: ≥ 140/90 mmHg 
b) Dyslipidemia: triglycerides (TGL) ≥ 150 mg/dl  and high-density 
lipoprotein cholesterol (HDL-C) <35 mg/dl (male),  or < 40 mg/dl 
(female) 
c) Central obesity: waist:hip ratio > 0.90 (male); > 0.85 (female), or body 
mass index > 30 kg/m2 
d) Microalbuminuria: urinary albumin excretion ratio ≥ 20 µg/min or 
albumin:creatinine ratio ≥ 30 mg/g 
38 
 
Associated diseases and signs are: hyperuricemia, fatty liver 
(especially in concurrent obesity) progressing to non-alcoholic fatty liver 
disease, polycystic ovarian syndrome (in women), and acanthosis nigricans. 
2.4   Studies   relating  Obesity  &  Microalbuminuria: 
1)  Jackson Heart  Study: - it deals  with prevalence of  microalbuminuria  in  
obese  non-diabetic, normotensive  African Americans. It  states  that  
obesity per  se  is  a major  risk  factor  for  renal  disease  even  in  the  
absence  of  diabetes. 
Summerso  et  al reported  that  the  prevalence of  microalbuminuria in 
obese individuals at 31.6% when  compared  to  normal  individuals. 
2)  Another  study by  Eyup Koc, Murat Suher, Gulden Bayrak in Ankara, 
Turkey , was done  on  the “ Effects  of  Anthropometric Measurements on 
Renal  function” – it  showed the prevalence of  microalbuminuria to be 
27.3% in persons  with  increased BMI, & 21.1% in persons with increased 
WC, & 29.2% in persons  with  increased  WHR. 
3 )  A large scale trial of Australian  adults was  carried  out  by Robert C. 
Atkins, Kevan R, Steven J. Chadban, Ester M for  prevalence  of  
microalbuminuria & for  its  associations. It concluded  by  saying  that 
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microalbuminuria  is  associated with  Hypertension in 64% of adults , 
20.7% of  smoking  adults,  13.5%  of  obese  adults. 
4 ) A study  done  by Christine M Hoehner, Kurt J Greenlund, Michelle L. 
Casper in Atlanta , USA, said  that  the  prevalence of  microalbuminuria  in  
nondiabetic  native  Americans , was 15.2% in relation to  other  traits  of  
Metabolic  syndrome. 
5 ) The  insulin  resistance atherosclerosis study  done by Leena Mykannen, 
Daniel J.Zaccaro, David C.Robbins, in Texas , USA, has shown  that 
microalbuminuria is  associated with  Insulin resistance in  non-diabetic 
obese  subjects. 
6 ) An article  by J S Sandhu, M Singla, A Ahuja, P Chopra from  Ludhiana, 
Punjab  have  dealt  in  detail  about  the  renal  risks  of  Obesity. It  quotes  
an increased  prevalence of microalbuminuria among  obese  individuals. 
7 ) Another  study by Prataap K. Chandie shaw, Stefan P. Bergar, Marko 
Mallat, Ton J Rabelink,  from The Hague , Netherlands, have  shown  that  
central  Obesity  is  an  independant  risk  factor for albuminuria in  non-
diabetic south  asian subjects. In  this  study  they  have  explored  the  
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hypothesis that central  obesity  is associated  with  development  of  renal  
injury,  prior to  the  manifestation of diabetes  or  hypertension. 
There  are many  studies  under  trial to  prove  the  link  between 
Obesity  & its  attendant  renal & CV risks , by  way  of  identifying  the 
prevalence  of  microalbuminuria  in  Obese  persons, so  that  early  
interventions  could  be  carried  out to halt  the progression  of  renal disease 
&  its  impact  on  Cardiovascular  system.  
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AIMS  &  OBJECTIVES   
1) To  study  the  prevalence  of  microalbuminuria  in  normoglycaemic- 
normotensive  obese  persons  (cases)  in comparison  with    
nonobese  persons (controls). 
 
2) To study  the  strength  of  correlation between  microalbuminuria & 
and  various  grades  of  obesity in  relation  to  body mass index 
(BMI)  among  the  cases. 
 
3) To  study  the  strength  of  correlation  between  microalbuminuria  &  
waist hip ratio (WHR)  in  both  males  and  females  among the cases. 
 
4) To study  the  strength  of  correlation  between  microalbuminuria  & 
waist circumference (WC)  in  both  males  and  females  among the 
cases. 
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                        MATERIALS   &  METHODS 
SETTING: 
This  study  was  done on  the  subjects  attending  for their  ailments   
to  the  out  patient  clinic of Govt  Rajaji Hospital, Madurai. 
DESIGN  OF  STUDY: 
A  Case – Control  study. 
PERIOD  OF  THE  STUDY: 
Over  Eight  Months  Period (March-2010  -October-2010) 
SAMPLE  SIZE  &  SELECTION OF  STUDY  SUBJECTS: 
Persons  who  attended  the  outpatient  clinic  of  Govt  Rajaji  
Hospital  for some  other  complaints,  &  who were  obese,  over  the  above  
eight  months  period were  screened  to  rule  out  hypertension , 
hyperglycemia, macroalbuminuria , dyslipidemia & after  ruling  out these  
conditions about  50  obese  persons (cases) were  included  along  with  50  
nonobese  persons (controls)  in this  study  from  the  above  same  period. 
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DETAILS  OF  STUDY  SUBJECTS: 
The  obese   &  nonobese  persons coming  to  the  out patient  
department for some  other complaints were  screened  for 
1) Blood  pressure- was recorded using sphygmomanometer  with  standard 
cuff   on  two  occasions  10  minutes  apart. Patient should  have  refrained 
from smoking  for atleast 30 minutes before  measuring  B.P. , & he  should  
be  calm. 
2)Persons   height &  weight  was  measured  in  the  O.P, and  the  patient’s  
BMI  was  calculated  using  the  formula  Weight / Height2. 
3)Persons   waist  circumference, hip  circumference  was  measured  with  
an  inch  tape  &  Waist-Hip  ratio  was  calculated. 
4)All  had  undergone lab  investigations for 
    a) Random  blood  sugar, serum  urea, creatinine &   Total  cholesterol  
was estimated by  an  AutoAnalyzer. 
   b) all  the  persons  had  routine  urine  analysis (albumin by  dipstick 
method,  sugar  &  deposits) done. 
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  c) A  12  lead  electrocardiogram was  taken. 
5) Finally  after  ruling  out hypertension, hyperglycemia, dyslipidemia, & 
macroalbuminuria  about  50  obese  persons  &  50 nonobese  persons  
underwent urine test  for microalbuminuria . 
Among  the  50  obese persons  26 were  males, & 24  were  females. 
PROCEDURE  OF  MICROALBUMINURIA  TEST: 
All  the  obese  & nonobese persons  selected by  the  above  method 
were  asked to report  the next  day  morning with first  voided  early  
morning  urine  sample  for  the  detection of  microalbuminuria. 
It  is a fully  automated  calibrated  system. Urine Albumin to 
Creatinine  ratio  in  the  given  sample  was  calculated. 
Albumin 
• Technology - fully  automated  immunoturbidimetric  assay 
• Method – photometry 
• Reference -  adults  range <18µg/ml 
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Creatinine 
• Technology –Modified JAFFE method  
• Method – Photometry 
• Reference  range  a) Males – 39-259 mg/dl 
b) Females – 28-217 mg/dl 
EXCLUSION   CRITERIA ( for cases  &  controls ) 
• Persons  with  RBS (Random Blood Sugar) >140mg/dl (Hyperglycemia) 
• Persons  with B.P  >120/80mm of hg (Hypertension & prehypertension) 
• Persons  with  Total  cholesterol > 200mg/dl (Dyslipidemia) 
• Persons  with  urea >40mg/dl  &  Creatinine > 1.2mg/dl 
• Persons with  Macroalbuminuria positive (Dip stick  method) 
• Persons  having  ischemic  changes  in ECG. 
• Elderly  persons >60 yrs 
• Persons who  are  chronic  Smokers 
Persons with  BMI <25  were  taken  as controls,  ≥25  as  cases. 
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ETHICAL  COMMITTEE  APPROVAL: 
Ethical  committee  clearance  was  obtained. 
CONSENT: 
Informed  consent were  obtained  from  all the  subjects (cases & 
controls). 
STATISTICAL  ANALYSIS: 
Computer  analysis  of  the  collected  data was  done  using  the  
software,  SPSS  Statistics Software  Version  17.0. The  Pearson Chi-
Square  Test  was  used  for  testing  the  significance  of  the  collected  data. 
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RESULTS AND ANALYSIS  
Table  No 5.1: 
MEASURES  OF  CENTRAL  TENDENCIES  AMONG           
VARIOUS  VARIABLES  IN  THE  STUDY  GROUP. 
  
  Age Ht Wt WC HC 
Cases Valid 50 50 50 50 50 
Missing 0 0 0 0 0 
Mean 37.96 165.14 81.72 95.52 97.38 
Median 39.50 166.00 80.00 95.00 98.00 
Mode 48 160 80 90 96 
Std. Deviation 8.978 5.249 8.531 7.579 4.911 
Range 38 24 34 31 20 
Minimum 16 154 64 81 88 
Maximum 54 178 98 112 108 
 
This  table  shows  the  various  variables  present  in the  study  group 
like  age, height, weight, waist circumference, & hip  circumference and  its  
measure  of  central  tendency  &  dispersion  including  the  maximum  &  
minimum  of  all the  variables. 
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Table   No  5.2: 
Comparison  of  prevalence  of  microalbuminuria  among  both  cases  &  
controls. 
 
Microalbuminuria  among  cases  &  controls 
   
MAU 
Total       Normal Micro 
Category Case Count 34 16 50 
% within 
Category 
68.0% 32.0%  
Control Count 48 2 50 
% within 
Category 
96.0% 4.0%  
Total Count 82 18 100 
% within 
Category 
82.0% 18.0%  
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Table  No 5.3: 
Chi-Square Test 
 Value Df Asymp. Sig. (2-sided) 
Pearson Chi-   Square 13.279a 1 .000 
 
In this  study  there  were a total  of  50  cases ( obese persons ) ,& 50  
controls ( non obese persons ) , who were  screened  for  microalbuminuria.   
Out  of  the  50  cases  16 persons  tested  positive  for  microalbuminuria, 
and  out  of  the 50  controls  only  2  persons  tested  for  microalbuminuria. 
Hence  among  the  obese group  who  had  normal  B.P & normal  Blood 
sugar , 16   had  microalbuminuria. But  in  the  control  group who  also  
had normal  B.P & normal blood  sugar , only  2  tested positive  for  
microalbuminuria. 
After  statistical  analysis of  these  values , according to  Chi-square 
test   the  p  value  is  <0.001 ,  which  is  statistically  significant, & hence it  
shows  that  obesity  itself  can  lead  to microalbuminuria & that  there  is  
strong  correlation  between  Obesity  &  Microalbuminuria.  
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Table  No 5.4: 
Prevalence  of  microalbuminuria  among  various  grades  of   
obesity  cases  based  on  BMI 
Category 
Microalbuminuria 
Total Normal Micro 
Case BMI  Overweight Count 26 3 29 
% within 
BMI  
89.7% 10.3%  
Obe_Grade1 Count 8 10 18 
% within 
BMI  
44.4% 55.6%  
Obe_Grade2 Count 0 3 3 
% within 
BMI  
.0% 100.0%  
Total Count 34 16 50 
% within 
BMI  
68.0% 32.0%   
 
Here  the  persons in  the  cases  list   were  divided  into 3  categories 
based  on the  BMI  value,  into  overweight , obesity  grade 1, & obesity 
grade 2. The  prevalence  of  microalbuminuria  among  all these categories  
were  tabulated  and  the  significance assessed. There was no obesity GR III 
persons in this study.  
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Table No 5.5: 
Chi-Square Tests 
Category Value df Asymp. Sig. (2-sided) 
Case Pearson Chi-
Square 
17.215a 2 .000 
Likelihood Ratio 18.666 2 .000 
Linear-by-Linear 
Association 
16.870 1 .000 
No of Valid Cases 50 
 
After  the  statistical  analysis , the Chi-Square  test  gives  the  p value  as 
<0.001  , which  is  statistically  very  significant. 
This  goes  on  to  show  that there  is  increasing  percentage of  the  cases  
with  microalbuminuria, with  increase in  grades  of  Obesity  according  to 
BMI. 
Hence  there  is  a strong  correlation  between  BMI &  Microalbuminuria. 
Among  the  overweight  category of  29  persons 3  had  microalbuminuria, 
among  18   grade 1 obesity persons  10  had  microalbuminuria, & among  3  
grade  2 obesity persons all had  microalbuminuria. 
So  from  this  study there  is  a significant  relation  between BMI & 
microalbuminuria. 
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Table  No 5.6: 
Prevalence  of  microalbuminuria  among   male  cases  based  on  WHR 
 
       WHR  &  MAU - Males: 
  
 
Microalbuminuria 
Total Normal Micro 
Male WHR Acceptable Count 2 0 2 
% within 
WHR 
100.0% .0%  
Unacceptable Count 17 7 24 
% within 
WHR 
70.8% 29.2%  
Total Count 19 7 26 
% within 
WHR 
73.1% 26.9%  
 
Here  the  acceptable  WHR  for  males  is  taken  as <0.90  & and  the  rest  
of  the  values  as  unacceptable WHR . 
Most  of  the  males ( 24 out  of  26  )  from  this  study come  under  the  
category  of  unacceptable WHR. Only  2  of  them  come  under  the  
acceptable  category, &  among  the  2 none  had  MAU.  
But  out  of  24 unacceptable  , 7  of  them  had  MAU i.e  29.2%  had  
microalbuminuria. Whether  this  value  is  significant  or  not , was  derived  
from  the  Chi- Square test. 
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Table  No  5.7: 
Chi  Square     Test 
Male Pearson Chi-Square .798 1 .372 
 
The  Chi-Square  test was  done  &  the  p  value  was >0.05, hence  it  
was  not  statistically  significant. Hence  the  relation  between WHR & 
microalbuminuria  is  by  mere  chance only, from this study. 
So  from  this  study  there  was  no significant  correlation  between  
WHR &  microalbuminuria  for  male  cases. But  since  most  of  them  
were  in  the  unacceptable  category , we could  not  exactly  say  whether  
WHR  has a correlation  with  microalbuminuria  or  not. Here in  the  study 
all the  positive  microalbuminurics  were  only  from  the  unacceptable  
WHR  category. 
To  find  out  the  strength of  correlation  between  WHR & MAU , 
there  should  be  more  no  of  acceptable  category  of    WHR   cases  also  
in  the  study &  the  study  sample  should  also  be  more, then  only  the  
exact  significance  could  be  arrived  at. 
Though the prevalence of microalbuminuria among unacceptable 
male cases based on waist hip ratio was high, it was statistically not 
significant.  
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Table  No  5.8: 
Prevalence  of  microalbuminuria  among   female  cases based on WHR 
WHR  &  MAU - Females: 
 
Microalbuminuria Total 
Normal Micro 
Female WHR Acceptable Count 3 0 3 
% within WHR 100.0% .0%  
Unacceptable Count 12 9 21 
% within WHR 57.1% 42.9%  
Total Count 15 9 24 
% within WHR 62.5% 37.5%  
 
Here  out of  a total  of  24  female  cases , 21 females were  in  the  
unacceptable  WHR category ( > 0.80 )  &  3 of  them were  in  the  
acceptable  WHR  category ( <0.80 ). 
Among  the  acceptable  category  none  had  microalbuminuria, but  
among  the unacceptable  category  9  of  them   had microalbuminuria. 
So  we  go  on  to find  out  the  statistical   significance  based  on  the  
Chi-Square  test. 
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Table No  5.9: Chi-Square Tests 
Sex Value df Asymp. Sig. (2-sided) 
Female Pearson Chi-Square 2.057a 1 .151 
 
 
   
 
So  from  the  above  chi-square  test , the  p value  is  >0.05, hence  
the   correlation  between WHR  & microalbuminuria  in  female   cases  is  
statistically  not significant.  
Hence  the  increased prevalence of  MAU  in  female  cases  among  
the  unacceptable  WHR  category  is  by  chance  only. There  is  no  
significant  correlation  between  them. 
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Table  No  5.10: 
Prevalence  of  microalbuminuria  among  male  cases  based  on WC. 
 
WC &  MAU - Males Microalbuminuria Total 
Normal Micro 
 
Male 
 
WC  
Acceptable Count 18 2 20 
% within WC  90.0% 10.0%  
Unacceptable Count 1 5 6 
% within WC  16.7% 83.3%  
Total Count 19 7 26 
% within WC  73.1% 26.9%  
 
Table  No 5.11: 
                              Chi-Square  Test. 
Sex Value df Asymp. Sig. (2-sided) 
Male Pearson Chi-Square 12.616c 1 .000
 
The  acceptable  WC  in  males  is  taken  as 102 cms. Above  this  
value  it  is  taken  as  unacceptable.  
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 Going  on  to  compare  the  prevalence  of  microalbuminuria among  
them,  we  have  20  male  cases within  the  acceptable  category &  2  
among  them  have  microalbuminuria. 
A total  of  6  male  cases were  among  the  unacceptable  category  of  
WC , &  among  them  5  had  microalbuminuria. 
The  statistical  significance  was  calculated  by   the  Chi-Square  
Test. The  p  value  was  < 0.001 , hence  it  was  very  significant. 
Hence  from  this  study  there  was  significant  correlation between  
WC  &  microalbuminuria  among  the  male  cases. 
So  male  cases  with  unacceptable  WC  had  more  prevalence  of  
microalbuminuria  than  with  acceptable  WC. 
 
 
 
 
 
 
 
 
 
58 
 
Table  No 5.12: 
Prevalence  of  microalbuminuria among  female cases  based  on  WC. 
WC &  MAU -Females 
 
Table  No 5.13: 
                               Chi-Square  Test 
Sex Value df Asymp. Sig. (2-sided) 
Female Pearson Chi-Square .336a 1 .562
 
The  acceptable  WC  value  for  females  is  taken  as <88 cms. 
Above  this  it  is  taken  as  unacceptable. 
 
Sex 
Microalbuminuria 
Total Normal Micro 
Female WC  Acceptable Count 5 2 7 
% within 
WC  
71.4% 28.6%  
Unacceptable Count 10 7 17 
% within 
WC  
58.8% 41.2%  
Total Count 15 9 24 
% within 
WC  
62.5% 37.5%  
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Out  of  a total  of  24  female  cases 17  were  in  the  unacceptable  
range  &  the rest  of  7  cases  were  in  the  acceptable  range. 
Among  the  acceptable  cases 2  of  them  had  microalbuminuria &  
among  the  unacceptable  cases 7  had  microalbuminuria. 
The  statistical  significance based  on  the  chi-square  test  was 
calculated. The  p  value  was >0.05, hence  this  correlation  was  not  
significant. 
Hence  from  this  study  it  shows  that  there  is  no  significant  
correlation  between  the  prevalence  of  microalbuminuria  &  WC  among  
the  female  cases. 
Through the prevalence of microalbuminuria among unacceptable 
female cases based on waist circumference was high, it was statistically not 
significant.  
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DISCUSSION 
In  the  present  study , there  were  50  persons  who  were  obese, &  
50  controls  who  were  Non-obese .  They  were  selected  based  on  BMI  
with value  ≥ 25  as  obese  &  <25  as  non-obese.  
 All  the  persons  had  normal  B.P  &  normal  blood  sugar. All  had  
total  cholesterol  < 200 mg/dl. All  had  their  urea  &  creatinine  within  
normal  range. Their  ECG  was  normal. Their  urine  was  Negative  for  
macroalbuminuria  by  dipstick  method. 
They  had  their  height,  weight, WC , & hip  circumference  
measured. From  these values  BMI  &  WHR  was  calculated. Then all the  
cases  &  controls had  their  urine  checked  for  microalbuminuria  to  find  
out  its prevalence. 
Among  the  50  obese cases  16  had  microalbuminuria  &  among   
the  50  non obese controls  only  2  had  microalbuminuria.  So  on  
comparing  the  prevalence  of  microalbuminuria  among  cases  &  
controls,  according  to  chi-square  test , the  p value  was  <0.001,  which  
was  highly  significant. 
So  persons  who  were  obese  had  significantly  high  
microalbuminuria  prevalence ( 32% ). It  was  comparable  to  the  jackson  
61 
 
heart  study among  the  African  Americans , in  which  the  prevalence  of  
microalbuminuria  among  obese  was  31.6%. 
BMI & MAU 
Next  among  the  cases we  studied  the  severity  of  correlation  of  
microalbuminuria  with  grades  of  obesity  based  on  BMI. The BMI  
based  classification of  obesity  is  common  to  both  males  &  females.   
So  based on  the  BMI  the  cases were  separated  into  overweight , grade I 
obesity,  grade  II obesity  categories. 
Then  we  studied  the  prevalence  of  microalbuminuria  among  the  
three categories. Among  29  overweight  cases  only   3  had  
microalbuminuria, among  18  grade  I  obesity  cases  10  of  them  had  
microalbuminuria, & among  3  grade II  obesity  cases  all of  them  had  
microalbuminuria. In this study nobody was in grade III obesity range.  
This  signifies  that  as  BMI  increases  the  prevalence  of  
microalbuminuria  also  increases. The  p  value  for  this  association  was 
<0.001 &  it  was  stastistically  highly  significant. 
The  inference  is  that  the  prevalence  of  microalbuminuria  
increases  with  increasing  grades  of  obesity. So  this  proves  that 
increasing  grades  of  obesity  is  an   independent  risk  factor  for  
microalbuminuria. 
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WHR & MAU  
Next  we  analysed  the  significance  between  WHR  &  
microalbuminuria  separately  among  the  male  &  female  cases. The  
acceptable  WHR  for  male  &  female  was  different,  hence  this  analysis. 
The  acceptable  WHR  for  males  was  <0.90 , hence  among  the  
male  cases 2  were  within  acceptable  limits , & the  rest  24  were  in  the  
unacceptable  range. The  prevalence  of  microalbuminuria   was  0  among  
2 acceptable  cases, 7  among  24  unacceptable  cases. 
The  p  value  for  this  association  was >0.05, which  was  not  
significant. So  the  correlation  between WHR  &  microalbuminuria  
among  male  obese  persons  was  not  significant. 
Even  though  the  prevalence  of  microalbuminuria  among  
unacceptable  male  persons  was  high  it  was  not  statistically significant, 
so   it  should  be  merely  by chance  only. 
Next  among  female  cases the  acceptable  WHR  was  <0.80.  In  
this  study  there  were  3  acceptable  &  21  unacceptable  female  cases. 
Among  the 3  acceptable cases  none  had microalbuminuria, &  among  the  
21  unacceptable  cases  9  had  microalbuminuria. 
The  p  value  for  this  association  was >0.05 ,  so  it  was  
statistically  not  significant. Though  only  unacceptable  cases  had  
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microalbuminuria  among  the  female  cases, it  should  be  by  mere  
chance  only  according  to  this  study. 
So  from  this  study  there  was  not  much  correlation between  
WHR  &  microalbuminuria  among  both  female  &  male  cases, though  
microalbuminuria  was  present  only  in  the  unacceptable  cases.  
But  to  exactly  define  the  correlation  between WHR ( which is  
indicative  of  visceral  adiposity )  among  obese  persons  &  
microalbuminuria  we  have  compare   equal  no  of  acceptable  &  
unacceptable  cases  &  assess  its  statistical  significance. 
WC & MAU 
Now  we  want  to  assess  the  strength  of  correlation  between  WC  
&  microalbuminuria  among  the  cases. 
For  the  male  obese  cases , < 102 cms  is  taken  as the  acceptable  
limit  of  WC.  In  this  study  among  the  male  cases  there  were  20  
acceptable  &  6  unacceptable  cases  based  on  the  WC. 
Among  20  acceptable  male  cases  2  had  microalbuminuria  & 
among  6  unacceptable  cases  5  had  microalbuminuria. The  p  value  for  
this  association was <0.001, which  was  highly  significant. Hence  there  is  
a  strong  correlation between  WC  &  microalbuminuria  among  male  
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cases. So  the  male  cases  who  had  unacceptable   WC  had  high  
prevalence  of  microalbuminuria  among  them. 
So  for  the  female  obese  cases the  acceptable  WC  was <88 cms. 
Hence  in  this  study  there  were  7  acceptable  female  cases  &  17  
unacceptable  female  cases  based  on  the  WC. Among  7  acceptable  
cases  2  of  them  had  microalbuminuria  &  among  17  unacceptable  
cases  7  had  microalbuminuria. 
The  p  value  for  this  association  was  >0.05 ,  so  it  was  
statistically  not  significant. So  there  is  no  direct  correlation between   
WC  &  microalbuminuria  among  the  female  cases  in  this  study. 
So  in  this  study , microalbuminuria  has  a  stronger  association  
with  obesity  independent  of  the  risk  factors  like  diabetes, hypertension  
&  dyslipidaemias. 
Hence  obesity  itself  with  increasing  grades  of  BMI  is  an  
independant  risk  factor  for  microalbuminuria. 
 Evaluation  of  microalbuminuria  is  recommended  as  a  screening  
tool  for  all  obese  persons , in  particular  with  reference  to  increasing  
grades  of   BMI, to  assess  the  future  risk  of  both kidney  disease  &  
cardiovascular  disease. 
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Therefore  urinary  screening  for  microalbumniuria  atleast  once  in  
a  year  is  a must  for  all obese  persons  to  prevent  the  development  of  
future  complications. 
Heightened  awareness  of  microalbuminuria  as  an  early  marker  of  
endothelial  dysfunction, makes  it  as  an  essential screening  tool  in  all  
obese  persons  atleast  once  in  a  year. 
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CONCLUSION 
 
1) In  this  study  of  50  cases  &  50  controls, the  prevalence  of  
microalbuminuria  was  found  to  be  high  among  the  obese  
persons. 
2) The  prevalence  of  microalbuminuria  in  obese  persons  was  
statistically  high in  correlation  with  the  increase in severity  of  
obesity , based  on  BMI. 
3) The  prevalence  of  microalbuminuria  was high among  both  male  
&  female  cases  with increase in WHR, but was not statistically 
significant. 
4) The  prevalence  of  microalbuminuria  was high among  male  cases 
with   increased  WC  and it was  highly statistically  significant. 
5) The  prevalence  of  microalbuminuria  was high among  female  cases 
with  increased WC  but it was  not  statistically  significant. 
6) Therefore  urinary  screening  for  microalbuminuria   in  all obese  
persons  should  be  done, to  prevent  the  development  of  future  
complications  like  cardiovascular  &  renal  disease. 
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PROFORMA 
NAME:                                                             AGE:           SEX: 
ADDRESS:                                                      OCCUPATION: 
                                                                         OP  NO: 
PRESENT  HISTORY: (NATURE  OF  COMPLAINTS ) 
PAST  HISTORY: 
HTN:           DM:    CAD:                                                       
COPD:  CKD:                 TB: 
PERSONAL  HISTORY: 
SMOKING:             ALCOHOLISM:   DRUG  ABUSE: 
FAMILY  HISTORY: 
HTN:                                                         DM: 
ANTROPOMETRY: 
HEIGHT:                          WEIGHT:                         BMI: 
WAIST  CIRCUM:            HIP  CIRCUM:                   WHR: 
GENERAL  EXAMINATION: 
FUNDUS:                                                   THYROID: 
XANTHELASMA:     ACANTHOSIS NIGRICANS 
FEATURES  OF  CUSHING’S  SYNDROME: 
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PULSE  RATE:                                BLOOD  PRESSURE: 
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SYSTEMIC  EXAMINATION: 
CVS:       RS: 
ABDOMEN:     CNS: 
INVESTIGATIONS: 
BLOOD  GLUCOSE:                            SERUM  UREA: 
SERUM  CREATININE:                      TOTAL  CHOLESTEROL: 
URINE – MACROALBUMINURIA (DIPSTICK): 
URINE – SUGAR: 
URINE – DEPOSITS: 
ECG  IN  ALL  LEADS: 
 
MICROALBUMINURIA:           SPOT  URINE  ALBUMIN  CREATININE  
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ABBREVIATIONS 
 
ACEI – Angiotensin converting enzyme inhibitor 
ADA – American diabetes association 
ARB – Angiotensin receptor blocker 
BIA – Bioelectrical impedance analysis 
BMI – Body mass index 
BP – Blood pressure 
CVD – Cardio vascular disease 
CT – Computed tomography 
DM – Diabetes mellitus 
ESRD – End stage renal disease 
FSGS – Focal segmental glomerulosclerosis 
GFR – Glomerular filtration rate 
HC – Hip circumference 
HT – Height 
HTN - Hypertension 
LDL – Low density lipoprotein 
MAU – Microalbuminuria 
PAI-1 – Plasminogen activator inhibitor-1 
RAS – Renin angiotensin system 
RBS -  Random Blood Sugar   
TGF-β – Transforming growth factor-β 
TGL – Triglyceride 
TNF-α – Tumor necrosis factor-α 
UACR – Urine albumin creatinine ratio 
UAE – Urine albumin excretion 
VAT – Visceral adiposity 
WC – Waist circumference 
WHR – Waist hip ratio 
WT - Weight 
 
 
 
 
 
 
 
 
